t-therapeutics.comCrawled Nov 6, 2026
T-Therapeutics raised $133 million in Series B financing, co-led by Advent Life Sciences and British Business Bank, with additional investments from Johnson & Johnson Innovation, Samsara BioCapital, M-Ventures, and Lilly.
T-Therapeutics Ltd occupies the top floor of One Granta in Granta Park, Cambridge.
T-Therapeutics One Granta Granta Park Cambridge CB21 6DP
$133 million Series B financing co-led by new investors Advent Life Sciences and British Business Bank, with additional new investments from Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Samsara BioCapital, M-Ventures and Lilly, joined by all existing major shareholders
$32 million new equity injection adds to previously announced $59 million. New investors Tencent and BGF joined by all existing major shareholders.
T-Therapeutics appoints Theodora Harold as Chief Executive Officer, reflecting Company’s ambitious growth plans and progression into therapeutic development.
Amelia Copas joined T-Therapeutics as COO in November 2025. Amelia has over 15 years’ industry experience. She brings with her a wealth of operational and finance experience across private and publicly-listed organisation in the US and the UK.
As Head of Immunology at T-Therapeutics, Chris combines deep scientific expertise and a strategic translational perspective to drive the development of impactful therapies for patients with chronic inflammatory and autoimmune diseases.
E-Chiang is the Executive Vice President of Research at T-Therapeutics, responsible for establishing the Research strategy, directing drug discovery and translational efforts to bring molecules to the developmental candidate stage, and continuously evolving the technology.
Marc is the Vice President of Business Development & Strategy at T-Therapeutics. He brings extensive biotech experience and a complementary skillset to the team with his background as a venture capital investor.
The company integrates expertise in biopharmaceutical drug development, single-cell genomics, machine learning, and structural biology.
UK One Granta Granta Park Cambridge CB21 6DP
The OpTiMus platform generates fully human TCRs with high specificity, enabling access to previously undruggable intracellular targets.
T-Therapeutics secures $133 million in Series B funding to develop two experimental TCR bispecific therapies targeting cancer and autoimmune diseases. The Cambridge-based biotech spinout plans to advance these T-cell engager treatments into clinical trials. This round increases the company’s total funding to $224 million.
Nov 2026European Biotechnology MagazineNews article
